Status:
COMPLETED
Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)
Lead Sponsor:
AbbVie
Conditions:
Multiple Myeloma (MM)
Eligibility:
All Genders
18+ years
Brief Summary
Multiple myeloma (MM) is a rare cancer caused by abnormal survival of plasma cells (blood cells). Most trial participants with MM relapse (cancer has come back) or become non- responsive to treatment ...
Eligibility Criteria
Inclusion
- \- Confirmed newly diagnosed or relapsed/refractory (R/R) Multiple myeloma (MM) who have signed informed consent for the use of their biological material for research purposes.
Exclusion
- \- Participants who do not have Bone Marrow (BM) and blood sample at time of diagnosis or at confirmation of relapse.
Key Trial Info
Start Date :
July 7 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2023
Estimated Enrollment :
514 Patients enrolled
Trial Details
Trial ID
NCT04721002
Start Date
July 7 2021
End Date
September 30 2023
Last Update
October 18 2023
Active Locations (40)
Enter a location and click search to find clinical trials sorted by distance.
1
Tulane School of Medicine /ID# 223864
New Orleans, Louisiana, United States, 70112
2
University of Texas Southwestern Medical Center /ID# 223865
Dallas, Texas, United States, 75390-7208
3
Hospital Italiano de Buenos Aires /ID# 224153
Ciudad Autonoma Buenos Aires, Buenos Aires F.D., Argentina, 1199
4
Alfred Health /ID# 224386
Melbourne, Victoria, Australia, 3004